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Background: Recent studies have identified several single-nucleotide polymorphisms (SNPs) associated with the
risk of breast cancer and parity and age at first childbirth are well established and important risk factors for breast
cancer. The aim of the present study was to examine the interaction between these environmental factors and
genetic variants on breast cancer risk.
Methods: The Malmö Diet and Cancer Study (MDCS) included 17 035 female participants, from which 728 incident
breast cancer cases were matched to 1448 controls. The associations between 14 SNPs and breast cancer risk were
investigated in different strata of parity and age at first childbirth. A logistic regression analysis for the per allele risk,
adjusted for potential confounders yielded odds ratios (OR) with 95% confidence intervals (CI).
Results: Six of the previously identified SNPs showed a statistically significant association with breast cancer risk:
rs2981582 (FGFR2), rs3803662 (TNRC9), rs12443621 (TNRC9), rs889312 (MAP3K1), rs3817198 (LSP1) and rs2107425
(H19). We could not find any statistically significant interaction between the effects of tested SNPs and parity/age at
first childbirth on breast cancer risk after adjusting for multiple comparisons.
Conclusions: The results of this study are in agreement with previous studies of null interactions between tested
SNPs and parity/age at first childbirth with regard to breast cancer risk.Background
The risk of breast cancer among first-degree relatives of
a breast cancer patient is about twice as high as in the
general population [1]. The genes BRCA1 and BRCA2
are associated with the risk of breast cancer [2], however
these genes account for only 30-40% of the familial
breast cancer cases, and only 3-4% of the total number
of breast cancer cases [2]. A much larger proportion of
all cases have been associated with environmental fac-
tors such as reproductive history, life-style and endogen-
ous hormonal levels. Two important factors associated
with breast cancer risk are parity and age at first child-
birth [3].
Genome wide association studies (GWAS) have re-
cently identified several single nucleotide polymorphisms
(SNPs) associated with breast cancer risk [4-7]. Certain* Correspondence: salma.butt@med.lu.se
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reproduction in any medium, provided the orcombinations of these polymorphisms and reproductive
factors could affect the susceptibility for breast cancer.
The Malmö Diet and Cancer Study (MDCS) is a pro-
spective population-based cohort in Malmö, Sweden. It
provides tumour endpoints, DNA samples, and informa-
tion on parity and other reproductive factors for a total
of 17 035 women. The aim of the present nested-case
control study was to study whether the reported associa-
tions between reported risk SNPs and breast cancer dif-
fer by parity and age at first birth.
Methods
The Malmö Diet and Cancer Study (The MDCS)
The MDCS, a population-based prospective cohort
study recruited participants between 1991 and 1996. All
female residents of Malmö, Sweden, born between 1923
and 1950 were invited. Written informed consent was
obtained by all participants at baseline. In all, 41% of
invited women participated, and the female cohort con-
sisted of 17 035 women [8]. Baseline examinations
included a questionnaire providing information on. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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marital status, age at menarche, age at menopause, ex-
posure to oral contraceptives (OC) (ever/never), current
use of hormonal replacement therapy (HRT), alcohol
consumption and smoking habits [9]. HRT was defined
as non-use, use of estrogen replacement therapy, proges-
terone replacement therapy or combined hormonal
replacement therapy. Information on gynecological sur-
gery was collected from medical records and meno-
pausal status was defined, using this information
together with data obtained from the questionnaire on
menstruations, as previously described in detail [10]. A
trained nurse at the study centre measured height and
weight, and Body Mass Index (BMI) was calculated as
kg/m2 [9].
The MDCS and the present analyses were approved by
the Ethical Committee at Lund University (LU 51–90,
Dnr 652/2005 and Dnr 2009/682).
Parity and age at first childbirth
Information on parity was assessed from the question-
naire. The question: “How many children have you given
birth to and in what years were they born?” was cate-
gorised as; nullipara, one child, two children and three
or more children. Parity was further dichotomized as
nulliparous and parous in order to yield larger groups.
Age at first childbirth was calculated from the informa-
tion provided in the same question and categorised as;
≤20, >20 - ≤25, >25 - ≤30 and >30. Age at first childbirth
was also dichotomized as ≤ 25 years of age and > 25 years
of age. Information on parity and age at first childbirth
was missing for a small number of women, and they
were excluded from all analyses. No reliable information
on twin pregnancies was available nor on miscarriages
or abortions.
Follow-up
All women were followed until 31st of December 2007.
Tumour end-points were retrieved by record linkage
with The Swedish Cancer Registry (until 31st of Decem-
ber 2006), and due to a delay in central registration, also
with linkage to its regional branch, The Southern Swed-
ish Regional Tumour Registry concerning 2007. Vital
status was obtained from The Swedish Cause-of-Death
Registry until 31st of December 2007.
Study population
All 17035 women were followed for cancer as described
above. For the purpose of the present study, only women
with no previous (prevalent) cancer (not including can-
cer in situ of the uterine cervix) were eligible for inclu-
sion. A total of 545 cases with incident breast cancer
were identified in a first set with follow-up until 31st of
December 2004. One case did not have any DNA samplehence this case was excluded. The remaining 544 cases
were matched to two controls each, a total of 1088. The
matching criteria were age (+/− 90 days) and time of
sampling at baseline (+/− 30 days). A new linkage was
performed with follow-up until 31st of December 2007,
where an additional 186 cases and 372 controls were
identified. A total of 11 controls from the first set were
diagnoses with breast cancer during the second follow-
up period. They were removed as controls and replaced
by other controls matched on the same criteria. For 14
women, there were no DNA available for sampling (2
cases and 12 controls); hence they were excluded from
all statistical analyses. Finally, the study population con-
sisted of a total of 2176 women out of which 728 were
cases and 1448 were controls.
SNP selection and analysis
Eleven SNPs were selected from previous GWAS and
candidate SNP publications by Easton et al. (rs2981582
(FGFR2), rs3803662 (TNRC9), rs12443621 (TNRC9),
rs98051542 (TNRC), rs889312 (MAP3K1), rs3817198
(LSP1), rs2107425 (H19), rs13281615 (8q24), rs981782
(5p12), rs30099 (5q), rs4666451 (2p)) [4], one from Cox
et al. (rs1045485 (CASP8)) [7], one from Stacey et al.
(rs13387042 (2q35)) [5] and one from Harlid et al.
(rs7766585 (ESR1)) [11]. The GWAS SNPs were chosen
from studies published up until the 1st of July 2007.
The tested SNPs were analysed in a previous larger
data set including other centres. For the current cohort,
a screening and a verification test was performed in
1605 individuals. The comparison showed concordant
results in 99% of analyses [11].
The SNP analyses were performed with a MALDI-
TOF mass spectrometer (SEQUENOM MassArray)
using iPLEX reagents and protocol (SEQUENOM) and
10 ng DNA as PCR template. Primer sets were from
Metabion (Martinsried, Germany). The laboratory meth-
ods have previously been described in detail [11].
The genotypes for the SNPs were defined as: homozy-
gous major allele (AA), heterozygote (Aa) and homozy-
gous minor allele (aa). In cases with minor allele
frequency (MAF) near 0.5, the same classification as that
used in previous studies was used.
Statistical methods
Cases and controls were compared with regard to estab-
lished and potential risk factors for breast cancer in
order to identify possible confounders.
An unconditional binary logistic regression model was
fitted to analyse the association between SNPs and
breast cancer. A per allele analysis was performed using
a continuous variable with the values 0 (AA), 1 (Aa),
and 2 (aa). The reported odds ratios (OR) with 95% con-
fidence intervals (CI) denotes the risk difference when
Table 1 Case–control status and distribution of potential confounders
Factor Category Case (n = 728) Control (n = 1448)
Column% (n) Mean (SD) in italics
Education O-level college 67.9 (494) 70.2 (1017)
A-level college 7.1 (52) 7.0 (101)
University 24.7 (180) 22.4 (325)
Missing 0.3 (2) 0.3 (5)
Type of occupation Manual worker 33.2 (242) 38.5 (557)
Non-manual worker 60.0 (437) 52.3 (757)
Employer-self-employed 5.5 (40) 8.1 (118)
Missing 1.2 (9) 1.1 (16)
Married/cohabiting No 33.7 (245) 33.4 (483)
Yes 66.3 (483) 66.6 (965)
Missing — —
Age at menarche ≤12 20.9 (152) 21.4 (310)
>12 to <15 52.2 (380) 53.8 (779)
≥15 26.0 (189) 23.8 (344)
Missing 1.0 (7) 1.0 (15)
Parity Nullipara 11.5 (84) 9.7 (141)
1 19.8 (144) 21.3 (309)
2 44.6 (325) 41.9 (607)
≥3 21.6 (157) 24.8 (359)
Missing 2.5 (18) 2.2 (32)
Age at first childbirth Nullipara 11.5 (84) 9.7 (141)
≤20 15.5 (113) 16.2 (234)
>20 to ≤25 34.8 (253) 36.3 (526)
>25 to ≤30 25.5 (186) 26.7 (387)
>30 10.2 (74) 8.8 (127)
Missing 2.5 (18) 2.3 (33)
Bilateral oophorectomy No 98.9 (720) 98.3 (1424)
Yes 1.1 (8) 1.7 (24)
Missing — —
Pre-/Perimenopausal 33.3 (482) 34.6 (252)
Age at menopause ≤45 11.9 (172) 11.5 (84)
>45 to <53 39.2 (567) 37.4 (272)
≥53 14.4 (209) 14.3 (104)
Missing 1.2 (18) 2.2 (16)
Exposure to OC (ever/never) No 46.8 (341) 49.0 (709)
Yes 53.0 (386) 50.8 (735)
Missing 0.1 (1) 0.3 (4)
Exposure to HRT (current/non) No, pre menopausal 23.0 (167) 21.1 (306)
No, peri-/post menopausal 49.3 (359) 59.4 (860)
ERT 5.1 (37) 6.3 (91)
PRT 1.2 (9) 0.5 (7)
CHRT 21.2 (154) 12.3 (178)
Missing 0.3 (2) 0.4 (6)
Height Mean (standard deviation) 164.3 (5.8) 163.8 (6.0)
Missing for both cases and controls
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Table 1 Case–control status and distribution of potential confounders (Continued)
Body mass index Mean (standard deviation) 25.6 (4.1) 25.5 (4.4)
Missing for both cases and controls
Alcohol consumption Nothing last year (teetotaler) 10.2 (74) 12.0 (174)
Something last year (not last month) 10.6 (77) 12.1 (175)
Something last month 79.0 (575) 75.6 (1094)
Missing 0.3 (2) 0.3 (5)
Smoking Never 43.4 (316) 43.2 (626)
Current 27.5 (200) 28.1 (407)
Ex 29.1 (212) 28.5 (413)
Missing 0.0 (0) 0.1 (2)
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addition ORs were calculated using the common allele
(AA) as reference group for risk estimates for the sepa-
rate genotypes in all analyses.
Parity and age at first birth was dichotomised as nul-
liparous vs. parous and ≤ 25 years of age at first child-
birth vs. age > 25 years of age at first childbirth.
Overall breast cancer risk was calculated with the low-
est groups as reference, adjusted for birth year and
year at baseline.
The SNP analyses were stratified on nulliparous vs.
parous women and on age ≤ 25 years of age at first child-
birth vs. age > 25 years of age at first childbirth. Parity
and age at first childbirth were also studied in four
categories.
In addition, the material was stratified on single geno-
types, and the breast cancer risk associated with parity
and increasing age at first birth was calculated. These
associations were reported using the p-values for the
continuous analysis.
All analyses were subsequently adjusted for matching
criteria, age and year of inclusion in study, and for po-
tential confounders. A potential confounder was defined
as a factor with a distribution difference exceeding 5%
units between cases and controls and only these factors
were included in the multivariate analysis.
In order to assess any potential interactions be-
tween selected SNPs and parity and between
selected SNPs and age at first birth, an interaction-
term was introduced in the logistic regression
model. A p-value < 0.05 was considered statistically
significant. In a third step, the p-value was cor-
rected for multiple comparisons according to Bon-
ferroni, i.e. divided by the number of comparison.
In the present study, performing 28 interaction ana-
lyses, the corrected p-value regarded as statistically
significant was 0.0018.
As part of a sensitivity analysis, all analyses were
repeated excluding women with information on less than
80% of SNPs in a single individual, as this may indicate apoor DNA quality. In these analyses 660 cases and 1310
controls were included.
Results
Case–control status and distribution of potential
confounders
Among the described variables, cases were more often
non-manual workers as compared to controls; 60% vs.
52% (Table 1). More cases were users of HRT, particu-
larly combined hormonal replacement therapy (CHRT),
as compared to controls 21% vs. 12% (Table 1). These
factors differed by at least 5% units between cases and
controls and were, hence, included in the multivariate
analyses. All other factors were similarly distributed be-
tween cases and controls.
Selected SNPs in relation to breast cancer risk
A breast cancer association was seen for six of the 14
tested SNPs; rs2981582 (FGFR2) 1.28 (1.12-1.47),
rs3803662 (TNRC9) 1.20 (1.04-1.39), rs12443621
(TNRC9) 1.19 (1.04-1.35), rs889312 (MAP3K1) 1.18
(1.02-1.36), rs3817198 (LSP1) 1.17 (1.10-1.35) and
rs2107425 (H19) 0.86 (0.75-0.99) (Table 2).
Selected reproductive risk factors in relation to breast
cancer risk
In the analyses of breast cancer risk associated with the
studied reproductive factors, we could see a borderline
decreased breast cancer risk for parous women as com-
pared to nulliparous women RR: 0.82 (0.62-1.10). For
age at first birth, there was no breast cancer association
(>25 years of age RR: 1.05 (0.87-1.28)).
Selected SNPs and breast cancer risk according to parity
and age at first birth
Only one interaction between the effects of the tested
SNPs (rs981782 (5p12)) and parity was found with re-
gard to breast cancer risk p = 0.02 (Table 3). This associ-
ation was not seen when stratifying on four parity
groups (Additional file 1: Appendix1). No association














CC 233/561 1.00 1.00 1.00
CT 356/653 1.31 (1.08-1.60) 1.31 (1.07-1.60) 1.31 (1.07-1.61)
TT 124/185 1.61 (1.23-2.12) 1.62 (1.23-2.13) 1.63 (1.23-2.16)
Per allele 1.28 (1.12-1.46) 1.28 (1.12-1.46) 1.28 (1.12-1.47)
rs1045485 (CASP8)
CC 185/374 1.00 1.00 1.00
CG 42/86 0.99 (0.66-1.49) 0.98 (0.65-1.48) 1.04 (0.69-1.58)
GG 8/10 1.62 (0.63-4.17) 1.61 (0.63-4.16) 1.73 (0.66-4.54)
Per allele 1.10 (0.79-1.51) 1.10 (0.80-1.54) 1.10 (0.79-1.54)
rs3803662 (TNRC9)
CC 353/780 1.00 1.00 1.00
CT 278/512 1.20 (0.99-1.46) 1.20 (0.99-1.46) 1.19 (0.98-1.45)
TT 64/95 1.49 (1.06-2.09) 1.49 (1.06-2.10) 1.47 (1.04-2.08)
Per allele 1.21 (1.05-1.40) 1.21 (1.05-1.40) 1.20 (1.04-1.39)
rs8051542 (TNRC9)
CC 192/443 1.00 1.00 1.00
CT 338/637 1.22 (0.99-1.52) 1.23 (0.99-1.52) 1.20 (0.97-1.50)
TT 149/272 1.26 (0.97-1.64) 1.27 (0.97-1.64) 1.24 (0.95-1.62)
Per allele 1.13 (1.00-1.29) 1.13 (1.00-1.29) 1.12 (0.99-1.28)
rs12443621 (TNRC9)
AA 195/451 1.00 1.00 1.00
AG 338/657 1.19 (0.96-1.47) 1.19 (0.96-1.47) 1.20 (0.97-1.49)
GG 165/275 1.39 (1.07-1.79) 1.39 (1.08-1.79) 1.42 (1.09-1.84)
Per allele 1.18 (1.04-1.34) 1.18 (1.04-1.34) 1.19 (1.04-1.35)
rs889312 (MAP3K1)
AA 322/737 1.00 1.00 1.00
AC 301/530 1.30 (1.07-1.58) 1.30 (1.07-1.58) 1.26 (1.03-1.53)
CC 66/118 1.28 (0.92-1.78) 1.28 (0.92-1.78) 1.29 (0.92-1.80)
Per allele 1.19 (1.04-1.37) 1.19 (1.04-1.37) 1.18 (1.02-1.36)
rs3817198 (LSP1)
TT 311/668 1.00 1.00 1.00
CT 282/555 1.09 (0.90-1.33) 1.09 (0.90-1.33) 1.06 (0.87-1.30)
CC 76/107 1.53 (1.10-2.11) 1.53 (1.11-2.11) 1.50 (1.08-2.09)
Per allele 1.18 (1.02-1.36) 1.18 (1.02-1.36) 1.17 (1.10-1.35)
rs2107425 (H19)
CC 361/637 1.00 1.00 1.00
CT 250/573 0.77 (0.63-0.94) 0.77 (0.63-0.94) 0.78 (0.64-0.95)
TT 68/145 0.83 (0.60-1.14) 0.83 (0.60-1.14) 0.83 (0.60-1.14)
Per allele 0.86 (0.74-0.99) 0.86 (0.74-0.99) 0.86 (0.75-0.99)
rs13281615 (8q24)
AA 245/533 1.00 1.00 1.00
AG 332/633 1.14 (0.93-1.40) 1.14 (0.93-1.40) 1.14 (0.93-1.40)
GG 117/204 1.25 (0.95-1.64) 1.25 (0.95-1.64) 1.25 (0.95-1.64)
Per allele 1.12 (0.98-1.28) 1.12 (0.98-1.28) 1.15 (1.00-1.31)
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Table 2 Overall breast cancer risk in relation to selected SNPs (Continued)
rs981782 (5p12)
TT 182/335 1.00 1.00 1.00
TG 352/685 0.95 (0.76-1.18) 0.95 (0.76-1.18) 0.91 (0.72-1.14)
GG 125/296 0.78 (0.59-1.03) 0.78 (0.59-1.03) 0.74 (0.56-0.98)
Per allele 0.89 (0.77-1.02) 0.89 (0.77-1.02) 0.87 (0.75-1.00)
rs30099 (5q)
CC 584/1139 1.00 1.00 1.00
CT 113/248 0.89 (0.70-1.13) 0.89 (0.70-1.14) 0.90 (0.71-1.16)
TT 11/12 1.79 (0.78-4.08) 1.79 (0.78-4.10) 1.79 (0.77-4.18)
Per allele 0.98 (0.79-1.21) 0.98 (0.79-1.22) 0.99 (0.80-1.24)
rs4666451 (2p)
GG 272/554 1.00 1.00 1.00
GA 299/574 1.06 (0.87-1.30) 1.06 (0.87-1.30) 1.08 (0.88-1.32)
AA 105/204 1.05 (0.80-1.38) 1.05 (0.79-1.38) 1.06 (0.80-1.40)
Per allele 1.03 (0.91-1.18) 1.03 (0.91-1.18) 1.04 (0.91-1.19)
rs13387042 (2q35)
AA 192/335 1.00 1.00 1.00
AG 330/657 1.08 (0.86-1.36) 1.08 (0.86-1.35) 1.08 (0.86-1.37)
GG 163/350 1.23 (0.95-1.59) 1.23 (0.95-1.59) 1.24 (0.96-1.62)
Per allele 0.90 (0.79-1.03) 0.90 (0.79-1.03) 0.90 (0.79-1.02)
rs7766585 (ESR1)
CC 518/1031 1.00 1.00 1.00
CT 172/348 0.98 (0.80-1.22) 0.98 (0.80-1.22) 0.98 (0.79-1.21)
TT 17/26 1.30 (0.70-2.42) 1.30 (0.70-2.42) 1.42 (0.76-2.67)
Per allele 1.03 (0.86-1.23) 1.03 (0.86-1.23) 1.03 (0.86-1.24)
* Adjusted for matching variables (age and year of inclusion in study).
** Adjusted for matching variables (age and year of inclusion in study), and for selected confounders (socioeconomic status and exposure to HRT).
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with regard to breast cancer risk. Moreover, no statisti-
cally significant interaction between the effects of tested
SNPs and parity/age at first childbirth on breast cancer
risk was seen after adjusting for multiple comparisons
(using the corrected p-value cut-off <0.0018).
In the per allele analyses, no clear patterns for risk
associations were seen in the stratified analyses (Table 3,
Table 4, Additional file 1: Appendix 1 and Appendix 2).
Sensitivity analysis including subjects with information on
at least 80% of SNPs
When including only women with information on at
least 80% of SNPs, the results were fairly similar in all
analyses but some analyses with borderline significant
ORs became significant when only individuals with in-
formation on ≥ 80% of all SNPs were analysed (data not
shown).
Discussion
The results of this present study are in agreement with
previous GWAS studies for six out of 14 SNPs. With re-
spect to breast cancer risk, there were no statisticallysignificant gene-environment interactions between par-
ity/age at first childbirth and SNPs and this is in agree-
ment with the results in three other large-scale
investigations [12-14].Methodological considerations
Representativity
A total of 40% of the invited women in Malmö partici-
pated in the MDCS and women in the MDCS have been
shown to have a higher incidence of breast cancer and
they may also be selected towards a slightly higher
socioeconomic status [8] than the general population.
However, as the present study use internal comparisons,
yielding relative risks rather than incidence rates, the im-
pact of a potential selection bias was probably limited.Reproductive factors
Parity and age at first birth were the main exposures of
this study and were obtained from questionnaires
answered at baseline. All women were 44 years or older
at baseline, hence unlikely to have given birth to more
children thereafter.
Table 3 Breast cancer risk in relation to selected SNPs with regard to parity
Rs nr (Gene) p-value
inter-action
Case/ control N Nulliparous OR*
(CI 95%)
Case/ control N Parous OR*
(CI 95%)
rs2981582 (FGFR2) 0.96
CC 30/52 1.00 200/493 1.00
CT 36/69 0.90 (0.48-1.69) 310/571 1.36 (1.09-1.69)
TT 16/15 1.88 (0.78-4.52) 104/167 1.55 (1.15-2.10)
Per allele 1.25 (0.82-1.91) 1.27 (1.10-1.46)
rs1045485 (CASP8) 0.93
CC 21/48 1.00 162/318 1.00
CG 7/14 1.08 (0.37-3.18) 35/71 1.03 (0.65-1.63)
GG 0/0 — 8/10 1.68 (0.64-4.42)
Per allele 0.93 (0.31-2.83) 1.12 (0.79-1.58)
rs3803662 (TNRC9) 0.58
CC 36/72 1.00 311/694 1.00
CT 33/54 1.32 (0.71-2.44) 238/446 1.17 (0.95-1.47)
TT 8/7 1.95 (0.61-6.29) 54/82 1.47 (1.01-2.14)
Per allele 1.33 (0.83-2.14) 1.19 (1.02-1.40)
rs8051542 (TNRC9) 0.15
CC 14/38 1.00 177/399 1.00
CT 41/66 1.56 (0.73-3.36) 289/558 1.14 (0.91-1.44)
TT 23/28 2.18 (0.93-5.14) 120/234 1.14 (0.86-1.52)
Per allele 1.47 (0.96-2.24) 1.08 (0.94-1.24)
rs12443621 (TNRC9) 0.95
AA 22/30 1.00 170/415 1.00
AG 35/79 0.68 (0.33-1.42) 295/565 1.28 (1.02-1.62)
GG 25/25 1.55 (0.67-3.61) 135/237 1.43 (1.08-1.89)
Per allele 1.25 (0.82-1.92) 1.20 (1.04-1.38)
rs889312 (MAP3K1) 0.11
AA 42/67 1.00 273/653 1.00
AC 33/59 0.83 (0.46-1.53) 261/461 1.31 (1.06-1.62)
CC 4/10 0.49 (0.14-1.77) 61/103 1.47 (1.03-2.09)
Per allele 0.77 (0.48-1.24) 1.24 (1.07-1.45)
rs3817198 (LSP1) 0.48
TT 37/68 1.00 271/591 1.00
CT 31/55 1.12 (0.60-2.11) 239/482 1.06 (0.85-1.31)
CC 8/4 4.38 (1.13-16.96) 68/100 1.48 (1.04-207)
Per allele 1.53 (0.93-2.51) 1.16 (0.99-1.35)
rs2107425 (H19) 0.12
CC 44/57 1.00 311/570 1.00
CT 27/57 0.54 (0.28-1.05) 213/498 0.80 (0.65-1.00)
TT 4/14 0.35 (0.11-1.19) 64/127 0.94 (0.67-1.31)
Per allele 0.58 (0.36-0.95) 0.91 (0.78-1.06)
rs13281615 (8q24) 1.00
AA 29/52 1.00 211/465 1.00
AG 37/61 1.11 (0.58-2.15) 290/558 1.18 (0.95-1.47)
GG 13/19 1.32 (0.55-3.15) 99/183 1.26 (0.93-1.70)
Per allele 1.14 (0.75-1.73) 1.13 (0.98-1.31)
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Table 3 Breast cancer risk in relation to selected SNPs with regard to parity (Continued)
rs981782 (5p12) 0.02
TT 15/38 1.00 162/290 1.00
TG 43/72 1.67 (0.79-3.53) 303/595 0.85 (0.67-1.09)
GG 14/16 2.66 (0.99-7.12) 107/273 0.65 (0.48-0.87)
Per allele 1.64 (1.01-2.67) 0.81 (0.70-0.94)
rs30099 (5q) 0.47
CC 66/101 1.00 505/1015 1.00
CT 14/34 0.68 (0.32-1.43) 97/205 0.95 (0.73-1.24)
TT 2/1 3.18 (0.26-39.46) 9/11 1.63 (0.66-4.06)
Per allele 0.89 (0.47-1.67) 1.02 (0.81-1.30)
rs4666451 (2p) 0.37
GG 26/51 1.00 237/494 1.00
GA 38/54 1.39 (0.69-2.59) 256/502 1.08 (0.87-1.34)
AA 15/20 1.30 (0.54-3.10) 88/180 1.02 (0.75-1.38)
Per allele 1.17 (0.77-1.79) 1.02 (0.89-1.18)
rs13387042 (2q35) 0.79
AA 22/35 1.00 164/292 1.00
AG 40/60 1.11 (0.55-2.25) 287/580 0.87 (0.68-1.11)
GG 16/36 0.69 (0.30-1.61) 140/308 0.80 (0.60-1.06)
Per allele 0.85 (0.56-1.28) 0.89 (0.78-1.03)
rs7766585 (ESR1) 0.10
CC 63/97 1.00 443/907 1.00
CT 18/33 0.76 (0.39-1.51) 150/310 0.99 (0.79-1.24)
TT 0/6 —— 17/20 1.91 (0.98-3.71)
Per allele 0.96 (0.82-1.12) 1.03 (0.97-1.10)
*Adjusted for: age, year of inclusion in study, socioeconomic status and exposure to HRT.
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SNP analysis method has been validated by repeating
the analyses twice, in a subset and the reproducibility
was very high [11]. In order to verify that the results
were not altered by damaged DNA, the analyses were
repeated including only women with results on 80% or
more of the SNP analyses. Following this, all results
were similar.Statistical power
Overall, the sample size of this study was fairly small,
yielding a statistical power issue. Many comparisons
were made and there is a potential risk of a type I error.
The replication of results concerning selected SNPs and
breast cancer risk was based on previous studies, and all
but one SNP showed associations in the expected direc-
tion (statistically significant for six out of 14 SNPs). This
strengthens the assumption that these results reflect
true associations and were not only the result of mul-
tiple comparisons. As these analyses are made with an
a priori hypothesis, the Bonferroni correction for mul-
tiple testing was not considered relevant. Concerninginteraction analyses and the stratified analyses, these
analyses were exploratory and hypothesis generating
hence corrections for multiple comparisons for the per-
formed interactions was considered valid. Due to few
individuals in the analyses, the confidence intervals
were wide and the statistical power was low which can
have lead to a type II error. In order to address the risk
of type II error, parity and age at first childbirth were
dichotomized yielding larger study groups. Moreover,
interaction term corrected for multiple comparisons
(Bonferroni correction) yielded no statistically signifi-
cant interactions.Previous studies
To our knowledge, four studies have been published
studying breast cancer risk and the potential interaction
between SNPs and parity/age at first childbirth [12-15].
The SNP rs2981582 (FGR2), was studied by Kawase et al.
and they found a high breast cancer risk for nulliparous
women and for women giving birth to one or two chil-
dren, carrying homozygote minor allele of rs2981582
(FGR2). In their study, a total of 456 cases and 912
Table 4 Breast cancer risk in relation to selected SNPs with regard to age at first child-birth








Age > 25 years
OR* (CI 95%)
rs2981582 (FGFR2) 0.47
CC 110/291 1.00 90/202 1.00
CT 191/352 1.49 (1.20-1.99) 119/219 1.18 (0.84-1.66)
TT 60/95 1.68 (1.13-2.51) 44/71 1.38 (0.87-2.20)
Per allele 1.33 (1.10-1.61) 1.17 (0.94-1.47)
rs1045485 (CASP8) 0.26
CC 104/192 1.00 58/126 1.00
CG 21/41 0.99 (0.55-1.80) 14/30 1.14 (0.55-2.34)
GG 3/7 0.88 (0.22-3.60) 5/3 3.21 (0.71-14.61)
Per allele 0.93 (0.58-1.49) 1.38 (0.79-2.42)
rs3803662 (TNRC9) 0.91
CC 185/419 1.00 126/275 1.00
CT 143/257 1.25 (0.95-1.37) 95/188 1.08 (0.78-1.51)
TT 31/53 1.32 (0.81-2.16) 23/29 1.72 (0.94-3.12)
Per allele 1.19 (0.97-1.46) 1.21 (0.94-1.55)
rs8051542 (TNRC9) 0.48
CC 112/256 1.00 65/143 1.00
CT 166/313 1.23 (0.91-1.65) 123/244 1.06 (0.73-1.53)
TT 68/149 1.01 (0.70-1.46) 52/85 1.36 (0.85-2.16)
Per allele 1.03 (0.86-1.23) 1.16 (0.92-1.46)
rs12443621 (TNRC9) 0.82
AA 104/269 1.00 66/146 1.00
AG 169/312 1.48 (1.10-2.01) 126/252 1.07 (0.74-1.55)
GG 79/146 1.45 (1.01-2.08) 56/91 1.39 (0.88-2.18)
Per allele 1.22 (1.02-1.46) 1.17 (0.93-1.46)
rs889312 (MAP3K1) 0.65
AA 153/371 1.00 120/282 1.00
AC 161/288 1.30 (0.99-1.71) 100/172 1.33 (0.95-1.86)
CC 37/68 1.38 (0.88-2.16) 24/35 1.61 (0.91-2.86)
Per allele 1.21 (1.00-1.48) 1.30 (1.02-1.65)
rs3817198 (LSP1) 0.17
TT 160/359 1.00 111/232 1.00
CT 139/287 1.05 (0.79-1.39) 100/195 1.04 (0.74-1.46)
CC 44/50 2.00 (1.27-3.14) 24/49 1.00 (0.58-1.73)
Per allele 1.27 (1.04-1.55) 1.02 (0.80-1.30)
rs2107425 (H19) 0.09
CC 191/329 1.00 120/240 1.00
CT 120/304 0.69 (0.52-0.91) 93/194 0.99 (0.71-1.39)
TT 35/78 0.78 (0.50-1.22) 29/49 1.19 (0.71-2.00)
Per allele 0.81 (0.66-0.99) 1.06 (0.83-1.33)
rs13281615 (8q24) 0.80
AA 124/290 1.00 87/175 1.00
AG 172/323 1.27 (0.95-1.69) 118/234 1.04 (0.74-1.48)
GG 54/107 1.25 (0.84-1.86) 45/76 1.27 (0.80-2.01)
Per allele 1.15 (0.95-1.83) 1.11 (0.89-1.39)
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Table 4 Breast cancer risk in relation to selected SNPs with regard to age at first child-birth (Continued)
rs981782 (5p12) 0.38
TT 88/173 1.00 74/117 1.00
TG 185/351 0.96 (0.70-1.32) 118/243 0.73 (0.50-1.06)
GG 67/169 0.71 (0.48-1.05) 40/104 0.60 (0.37-0.96)
Per allele 0.85 (0.70-1.03) 0.77 (0.61-0.98
rs30099 (5q) 0.31
CC 299/621 1.00 206/393 1.00
CT 54/108 1.02 (0.71-1.46) 43/97 0.83 (0.55-1.25)
TT 6/6 2.47 (0.77-7.91) 3/5 0.76 (0.16-3.62)
Per allele 1.14 (0.83-1.56) 0.85 (0.59-1.23)
rs4666451 (2p) 0.24
GG 131/301 1.00 106/192 1.00
GA 159/295 1.23 (0.92-1.64) 97/207 0.89 (0.63-1.26)
AA 53/109 1.11 (0.75-1.65) 35/71 0.90 (0.56-1.45)
Per allele 1.09 (0.91-1.31) 0.93 (0.74-1.17)
rs13387042 (2q35) 0.89
AA 95/168 1.00 69/124 1.00
AG 170/348 0.86 (0.63-1.19) 117/232 0.89 (0.61-1.30)
GG 84/186 0.80 (0.55-1.15) 56/121 0.84 (0.54-1.31)
Per allele 0.89 (0.74-1.07) 0.92 (0.74-1.14)
rs7766585 (ESR1) 0.60
CC 249/525 1.00 194/382 1.00
CT 99/199 1.07 (0.80-1.43) 51/110 0.88 (0.60-1.29)
TT 11/13 2.06 (0.89-4.75) 6/7 1.68 (0.55-5.19)
Per allele 1.07 (0.98-1.18) 0.98 (0.90-1.08)
*Adjusted for: age, year of inclusion in study, socioeconomic status and exposure to HRT.
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study; however they only included one SNP [15].
The study by Travis et al. examined 120 gene-
environmental interactions (i.e. reproductive, behavioural,
and anthropometric risk factors for breast cancer) categor-
ising parity as nulliparous vs. parous and age at first child-
birth as younger or older than 25 years of age in 7610
cases and 10 196 controls, making the results less vulner-
able to type II error. They studied 12 SNPs and did not
find any statistically significant interaction. Four of the
SNPs examined in the present study (rs8051542 (TNRC9),
rs12443621 (TNRC9), rs2107425 (H19) and rs7766585
(ESR1)) were not studied by Travis et al. [12].
Milne et al. studied ten GWAS SNPs and two candi-
date SNPs associated with breast cancer in 26349 inva-
sive breast cancer cases and 32208 controls with regard
to interaction with reproductive factors. After adjust-
ment for multiple comparisons no significant association
was seen for parity (continuous and categorical) or age
at first childbirth (continuous and categorical). Five of
the studied SNPs by Milne et al. are the same as in
this study: rs2981582 (FGFR2), rs889312 (MAP3K1),
rs3817198 (LSP1), rs13281615 (8q24) and rs13387042(2q35). The other seven SNPs studied by Milne et al.
have been studied in more recent GWAS studies and are
hence not included in the present study [13]. Due to dif-
ferences in SNP selection, all results from this study may
not be comparable to the results of Milne et al.. How-
ever, three of the SNPs studied by Milne et al. are from
same genes as in this study 5p12, CASP8 and ESR1.
Campa et al. studied 17 SNPs associated with breast
cancer risk. When analysing gene-environmental risks
including parity and other reproductive factors, no sta-
tistically significant association was seen. The study of
Campa et al. included 8575 cases and 11892 controls,
making this study less vulnerable to type II errors. Seven
of the studied SNPs of Campa et al are the same as in
the present study and one is on the same gene, making
some of the results comparable to the present study.Conclusions
The results of this present study are in agreement with
previous GWAS studies in SNPs and breast cancer risk
for six out of 14 risk SNPs and is in agreement of null
results for SNP parity/age at first childbirth interaction.
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